Vitamin D Status in Children With High-risk Neuroblastoma

被引:2
|
作者
Izurieta-Pacheco, Ana Carolina [1 ,2 ]
Sangros-Gimenez, Ana [1 ]
Martinez-Garcia, Esther [1 ]
Perez-Jaume, Sara [1 ]
Mora, Jaume [1 ]
Gorostegui-Obanos, Maite [1 ]
机构
[1] Hosp St Joan Deu, Pediat Canc Ctr Barcelona, Barcelona, Spain
[2] Hosp St Joan Deu, Pediat Canc Ctr Barcelona, Oncol Dept, Passeig St Joan Deu 2, Esplugas de Llobregat 08950, Barcelona, Spain
关键词
vitamin D; high-risk neuroblastoma; childhood cancer; NEWLY-DIAGNOSED CHILDREN; D DEFICIENCY; 1,25-DIHYDROXYVITAMIN D-3; CANCER-PATIENTS; D-RECEPTOR; PREVALENCE; PREVENTION; NUTRITION; MORTALITY; SURVIVORS;
D O I
10.1097/MPH.0000000000002762
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background:Vitamin D deficiency has become a matter of concern in pediatric cancer patients. A relationship between neuroblastoma and Vitamin D signaling pathways has been revealed with interest in the antiproliferative and antiinvasive properties of vitamin D. Our aim is to describe the prevalence of Vitamin D deficiency among children with high-risk neuroblastoma (HR-NB) and to explore its association with disease status.Materials and Methods:In all, 182 patients with HR-NB were managed at our center from 2017 to 2021. Serum 25(OH)D levels were tested at the first blood analysis performed and correlated with clinical data and disease status.Results:One hundred forty-eight (81.4%) had low 25(OH)D levels (48.4% categorized as deficiency (25(OH)D below 20 ng/mL) and 33.0% as insufficiency (25(OH)D 20 to 30 ng/mL). Median Vitamin D level was 20.2 ng/mL. Vitamin D levels were not associated with race or sex. Although malnourished patients had lower median 25(OH)D levels(11.1 ng/mL), no statistical association was observed with Vitamin D deficiency. There was no association between Vitamin D levels and disease status. An inverse correlation was found between age and vitamin D levels (P=0.0040).Conclusion:A concerning high prevalence of low Vitamin D levels affects more than two-thirds of patients with HR-NB in our cohort, regardless of the disease status at the time of evaluation. Older children are at a higher risk for deficient levels of vitamin D.
引用
收藏
页码:E953 / E958
页数:6
相关论文
共 50 条
  • [31] Mouse models of high-risk neuroblastoma
    Alvin Kamili
    Caroline Atkinson
    Toby N. Trahair
    Jamie I. Fletcher
    Cancer and Metastasis Reviews, 2020, 39 : 261 - 274
  • [32] HIGH-RISK NEUROBLASTOMA: A Therapy in Evolution
    Fong, Abraham
    Park, Julie R.
    PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2009, 26 (08) : 539 - 548
  • [33] Mouse models of high-risk neuroblastoma
    Kamili, Alvin
    Atkinson, Caroline
    Trahair, Toby N.
    Fletcher, Jamie I.
    CANCER AND METASTASIS REVIEWS, 2020, 39 (01) : 261 - 274
  • [34] High-Risk Neuroblastoma Treatment Review
    Smith, Valeria
    Foster, Jennifer
    CHILDREN-BASEL, 2018, 5 (09):
  • [35] The genetic landscape of high-risk neuroblastoma
    Trevor J Pugh
    Olena Morozova
    Edward F Attiyeh
    Shahab Asgharzadeh
    Jun S Wei
    Daniel Auclair
    Scott L Carter
    Kristian Cibulskis
    Megan Hanna
    Adam Kiezun
    Jaegil Kim
    Michael S Lawrence
    Lee Lichenstein
    Aaron McKenna
    Chandra Sekhar Pedamallu
    Alex H Ramos
    Erica Shefler
    Andrey Sivachenko
    Carrie Sougnez
    Chip Stewart
    Adrian Ally
    Inanc Birol
    Readman Chiu
    Richard D Corbett
    Martin Hirst
    Shaun D Jackman
    Baljit Kamoh
    Alireza Hadj Khodabakshi
    Martin Krzywinski
    Allan Lo
    Richard A Moore
    Karen L Mungall
    Jenny Qian
    Angela Tam
    Nina Thiessen
    Yongjun Zhao
    Kristina A Cole
    Maura Diamond
    Sharon J Diskin
    Yael P Mosse
    Andrew C Wood
    Lingyun Ji
    Richard Sposto
    Thomas Badgett
    Wendy B London
    Yvonne Moyer
    Julie M Gastier-Foster
    Malcolm A Smith
    Jaime M Guidry Auvil
    Daniela S Gerhard
    Nature Genetics, 2013, 45 : 279 - 284
  • [36] Eflornithine for treatment of high-risk neuroblastoma
    Jiang, Jianxiong
    Yu, Ying
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2024, 45 (06) : 577 - 578
  • [37] Dinutuximab: A Review in High-Risk Neuroblastoma
    Hoy, Sheridan M.
    TARGETED ONCOLOGY, 2016, 11 (02) : 247 - 253
  • [38] A Safer Regimen for High-Risk Neuroblastoma
    Felix, Carolyn A.
    PEDIATRIC BLOOD & CANCER, 2009, 53 (01) : 3 - 6
  • [39] Immunocombination therapy for high-risk neuroblastoma
    Kroesen, Michiel
    Lindau, Dennis
    Hoogerbrugge, Peter
    Adema, Gosse J.
    IMMUNOTHERAPY, 2012, 4 (02) : 163 - 174
  • [40] Rethinking high-risk neuroblastoma treatment
    Cohn, Susan L.
    Pearson, Andrew D. J.
    PEDIATRIC BLOOD & CANCER, 2022, 69 (08)